29 active not recruiting, 14 completed, 14 recruiting, 10 terminated. 31 Phase 2, 21 Phase 1, 15 Not applicable, 12 Phase 3, 1 Early Phase 1.
Follow Stage IIIB Lung Cancer AJCC v8: new trials by email Literature Review of Stage IIIB Lung Cancer AJCC v8 trials Research Report on Stage IIIB Lung Cancer AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer Biospecimen Collection, Cemiplimab, Cetuximab Sarotalocan Sodium - Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2026-08-15 | 2026-09-15 | |
| Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial Adagrasib, Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody - Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8 | Phase 2 | Recruiting | City of Hope Medical Center | 535 | 2026-05-01 | 2026-10-16 |
| Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer Biospecimen Collection, Ceralasertib, Computed Tomography - Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 630 | 2025-08-07 | 2026-09-21 |
| Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer Biospecimen Collection, Cemiplimab, Fianlimab - Lung Non-Small Cell Carcinoma, Stage IB Lung Cancer AJCC v8 | Phase 2 | Recruiting | Mayo Clinic | 60 | 2025-05-02 | 2026-10-01 |
| Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial Biospecimen Collection, Computed Tomography, Durvalumab - Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 | Phase 3 | Recruiting | National Cancer Institute (NCI) | 306 | 2025-04-01 | 2026-10-19 |
| Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer Surgical Procedure, Cisplatin, Carboplatin - Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 | Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 37 | 2024-12-11 | 2026-09-02 |
| Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial Carboplatin, Computed Tomography, Magnetic Resonance Imaging - Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8 | Phase 3 | Recruiting | National Cancer Institute (NCI) | 304 | 2024-07-19 | 2026-10-22 |
| Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and Lung Best Practice, Nicotine Replacement, Quality-of-Life Assessment - Head and Neck Squamous Cell Carcinoma, Lung Non-Small Cell Carcinoma | Not applicable | Withdrawn | Ohio State University Comprehensive Cancer Center | 2024-01-01 | 2024-04-12 | |
| EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer EMB-01, Osimertinib - Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Unknown | Shanghai EpimAb Biotherapeutics Co., Ltd. | 115 | 2023-06-01 | 2023-06-01 |
| Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer Atezolizumab and Recombinant Human Hyaluronidase, Survey Administration - Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 | Phase 2 | Active not recruiting | University of Southern California | 5 | 2022-12-07 | 2026-01-29 |
| Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative Biopsy Procedure, Biospecimen Collection, Computed Tomography - Lung Adenocarcinoma, Lung Adenosquamous Carcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 427 | 2022-10-07 | 2026-10-01 |
| Remote Monitoring With Health-Coaching for Lifestyle Changes in Patients With Lung Cancer Related Fatigue Exercise Counseling, Exercise Intervention, Internet-Based Intervention - Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 | Not applicable | Terminated | Mayo Clinic | 7 | 2022-08-17 | 2025-02-07 |
| Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors Antineoplastic Immune Cell, Atezolizumab, Biospecimen Collection - Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 1 | Active not recruiting | University of California, Irvine | 6 | 2022-07-20 | 2026-10-06 |
| Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial Best Practice, Exercise Intervention, Physical Therapy - Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Small Cell Carcinoma | Not applicable | Completed | Ohio State University Comprehensive Cancer Center | 100 | 2022-04-14 | 2025-11-21 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) Cobalamin, Dexamethasone, Docetaxel - Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 2 / Phase 3 | Active not recruiting | SWOG Cancer Research Network | 82 | 2022-03-15 | 2026-05-18 |
| Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer Biopsy, Osimertinib, Triptolide Analog - Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 8 | 2022-03-07 | 2026-03-05 |
| Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer Aurora A Kinase Inhibitor LY3295668, Osimertinib - Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 32 | 2022-02-17 | 2026-09-18 |
| ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy Cisplatin, Durvalumab, Etoposide - Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 | Phase 2 | Terminated | University of Washington | 1 | 2021-12-10 | 2023-06-13 |
| Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer Carboplatin, Durvalumab, Paclitaxel - Locally Advanced Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 | Phase 1 | Recruiting | Ohio State University Comprehensive Cancer Center | 28 | 2021-12-06 | 2026-06-30 |
Showing 20 of 73. Sign in to see all of them.
Lung Neoplasms (73) · Carcinoma, Non-Small-Cell Lung (40) · Colorectal Neoplasms (5) · Melanoma (4) · Neoplasm Metastasis (4) · Squamous Cell Carcinoma of Head and Neck (4) · Carcinoma, Renal Cell (3) · Ovarian Neoplasms (3) · Small Cell Lung Carcinoma (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Transitional Cell (2) · Liver Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Ureteral Neoplasms (2) · Urinary Bladder Neoplasms (2)
Lung Diseases (73) · Neoplasms by Site (73) · Respiratory Tract Diseases (73) · Respiratory Tract Neoplasms (73) · Thoracic Neoplasms (73) · Neoplasms (72) · Bronchial Neoplasms (42) · Carcinoma, Bronchogenic (42) · Neoplasms by Histologic Type (12) · Carcinoma (9) · Digestive System Diseases (9) · Neoplasms, Glandular and Epithelial (9) · Digestive System Neoplasms (8) · Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8)
Immunoglobulin G (16) · Disulfides (15) · Specimen Handling (14) · Pemetrexed (13) · Carboplatin (12) · Magnetic Resonance Spectroscopy (12) · pembrolizumab (12) · Nivolumab (10) · durvalumab (10) · Paclitaxel (9) · Taxes (9) · Radiation (7) · Radiotherapy (7) · Cisplatin (6) · osimertinib (6)
M.D. Anderson Cancer Center (23) · National Cancer Institute (NCI) (11) · City of Hope Medical Center (8) · Ohio State University Comprehensive Cancer Center (6) · Mayo Clinic (5) · Roswell Park Cancer Institute (5) · Jonsson Comprehensive Cancer Center (2) · SWOG Cancer Research Network (2) · Alliance for Clinical Trials in Oncology (1) · Emory University (1) · OHSU Knight Cancer Institute (1) · Rahul Aggarwal (1) · Rutgers, The State University of New Jersey (1) · Shanghai EpimAb Biotherapeutics Co., Ltd. (1) · University of California, Davis (1)
United States (70) · Guam (4) · Puerto Rico (2) · Canada (1) · Chile (1) · China (1) · Colombia (1) · Mexico (1)
Kathrin Milbury (2) · Saumil Gandhi (2) · Xiuning Le (2) · Anne Reb (1) · Anne Reb, NP, PhD (1) · Anne S Tsao (1) · Anurag K Singh (1) · Arya Amini (1) · Aung Naing, MD (1) · Betty Ferrell (1) · Carl M Gay, MD,PHD (1) · Carlos E. Vargas, M.D. (1) · Carolyn J Presley, MD (1) · Carolyn J Presley, MD, MHS (1) · Carolyn Presley, MD (1)
PMID 41747891, PMID 42335416, PMID 33415649, PMID 33878954, PMID 33909232, PMID 34036820, PMID 34562230, PMID 34663123, PMID 34965890, PMID 35297944, PMID 35537412, PMID 35613998, PMID 36040670, PMID 37129197, PMID 37328287, PMID 38197040, PMID 38351528, PMID 38572955, PMID 39816915, PMID 39886125, PMID 39903538, PMID 39945382, PMID 40580957, PMID 41911908, PMID 42830627
P30CA033572 (6), U10CA180820 (5), U10CA180821 (3), U10CA180888 (2), K07CA215546 (1), K76AG074923 (1), P30CA014089 (1), P30CA016672 (1), P30CA060553 (1), P30CA072720 (1), P30CA093373 (1), P30CA138292 (1), R01CA155196 (1), R01CA222382 (1), R01CA249501 (1)